Gagnon, M.; Savard, M.; Tran, T.M.H.; Vincent, L.; Moquin, A.; Tremblay, P.; Roucou, X.; Dory, Y.; Gobeil, F.
Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules 2023, 28, 5206.
https://doi.org/10.3390/molecules28135206
AMA Style
Gagnon M, Savard M, Tran TMH, Vincent L, Moquin A, Tremblay P, Roucou X, Dory Y, Gobeil F.
Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules. 2023; 28(13):5206.
https://doi.org/10.3390/molecules28135206
Chicago/Turabian Style
Gagnon, Maxime, Martin Savard, Thi Minh Hue Tran, Laurence Vincent, Alexandre Moquin, Philippe Tremblay, Xavier Roucou, Yves Dory, and Fernand Gobeil.
2023. "Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease" Molecules 28, no. 13: 5206.
https://doi.org/10.3390/molecules28135206
APA Style
Gagnon, M., Savard, M., Tran, T. M. H., Vincent, L., Moquin, A., Tremblay, P., Roucou, X., Dory, Y., & Gobeil, F.
(2023). Evaluation of Novel B1R/B2R Agonists Containing TRIOZAN™ Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease. Molecules, 28(13), 5206.
https://doi.org/10.3390/molecules28135206